EyePoint, Inc. (EYPT)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$0.39-2.48%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · EYPT
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -62.6% |
| Our one-year growth estimate | diamond | -60.0% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 2.6 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name is on a run of consecutive earnings misses and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
EYPT — earnings miss
Dated 2026-10-19
Results of Operations and Financial Condition. On October 19, 2026, EyePoint, Inc. (the “Company”) issued a press release announcing, among other things, its estimated cash, cash equivalents and short-term investments as of September 30, 2026. The amounts included in the press release are preliminary, have not been reviewed by the Company’s independent registered public accounting firm and are subject to change upon completion of the Company’s unaudited financial statements for the fiscal qua…
Why it matters: The company announced cuts on October 19, but savings are not yet shown in reported results. The next report can set a cost base.
Watch forThe November 4 report shows a lower rate of operating costs. It also confirms progress toward about $30 million in yearly savings.
Also watch forThe report shows no lower cost run rate, or reports costs tied to the plan above the stated $9 million estimate.
Why it matters: Both Phase 3 wet AMD trials missed the main vision goal. EyePoint said it would review the data before deciding next steps.
Watch forEyePoint names a clear path to keep developing a wet AMD treatment. Its pooled trial review and added data support this path.
Also watch forEyePoint ends wet AMD development or says the pooled trial data do not support further work.
Why it matters: These two trials are now EyePoint’s main clinical test. They will show whether DURAVYU can match aflibercept on vision and cut injection burden.
Watch forBoth trials meet the main vision goal at Weeks 52 and 56. They are no worse than aflibercept and need fewer treatments.
Also watch forEither trial misses the main vision goal, or neither shows lower treatment burden than aflibercept.
Why it matters: EyePoint estimated $118 million in cash and investments at September 30. The DME trial results are due in Q4 2027, so cash use matters.
Watch forThe final quarter report confirms at least $118 million in cash and investments. Management keeps its stated runway through the Q4 2027 DME readout.
Also watch forThe final cash figure is below $118 million, or management says funds may not last through the Q4 2027 DME readout.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$369 on $10,000 · ±3.7% | How much price usually moves either way. |
| Bad day | $814 loss on $10,000 · 8.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,815 loss on $10,000 · 98.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The planned cuts support EyePoint’s cost-saving plan. Delay or added costs could weaken cash conservation.
Watch forEyePoint reports that the workforce cuts are complete by the first half of 2027 and confirms about $30 million in yearly savings.
Also watch forThe cuts are still incomplete after the first half of 2027, or EyePoint lowers its stated yearly savings estimate.